FDA Awards Priority Review Voucher for Rare Pediatric Disease Treatment
January 15, 2025
January 15, 2025
WASHINGTON, Jan. 15 (TNSFR) -- The Food and Drug Administration (FDA) has granted a priority review voucher to Novo Nordisk, Inc. for ALHEMO (concizumab-mtci), a treatment for hemophilia A and B with inhibitors.
Approved on December 20, 2024, ALHEMO is indicated for routine prophylaxis to prevent or reduce bleeding episodes in patients aged 12 and older.
This award is part of the FDA's Rare Pediatric Disease Priority Review Voucher Program, which incentivizes the . . .
Approved on December 20, 2024, ALHEMO is indicated for routine prophylaxis to prevent or reduce bleeding episodes in patients aged 12 and older.
This award is part of the FDA's Rare Pediatric Disease Priority Review Voucher Program, which incentivizes the . . .